Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synlogic, Inc.    SYBX

SYNLOGIC, INC.

(SYBX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2019 | 08:06am EDT

By Colin Kellaher

Synlogic on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.

Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.

Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG 0.07% 287.4 Delayed Quote.19.97%
ROCHE HOLDING AG -0.14% 245.6 Delayed Quote.14.10%
ROCHE HOLDING AG -0.07% 289.25 Delayed Quote.18.88%
SYNLOGIC, INC. -1.81% 2.17 Delayed Quote.-69.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNLOGIC, INC.
09/30SYNLOGIC : to Present at the Chardan 3rd Annual Genetic Medicines Conference
BU
09/04SYNLOGIC, INC. : Change in Directors or Principal Officers, Financial Statements..
AQ
09/04SYNLOGIC : Announces Appointments of New CMO, Head of Regulatory Affairs, and CF..
BU
09/04SYNLOGIC : Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposi..
BU
08/20SYNLOGIC, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
08/20SYNLOGIC : Discontinues Development of SYNB1020 to Treat Hyperammonemia
BU
08/13SYNLOGIC, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
08/08SYNLOGIC : to Present at the 2019 Wedbush PacGrow Healthcare Conference
BU
08/08SYNLOGIC : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/08SYNLOGIC, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
More news
Financials (USD)
Sales 2019 1,58 M
EBIT 2019 -57,6 M
Net income 2019 -55,6 M
Finance 2019 121 M
Yield 2019 -
P/E ratio 2019 -1,12x
P/E ratio 2020 -1,13x
EV / Sales2019 -32,6x
EV / Sales2020 12,7x
Capitalization 68,8 M
Chart SYNLOGIC, INC.
Duration : Period :
Synlogic, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNLOGIC, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 9,19  $
Last Close Price 2,17  $
Spread / Highest target 545%
Spread / Average Target 323%
Spread / Lowest Target -7,83%
EPS Revisions
Managers
NameTitle
Aoife M. Brennan President, Chief Executive Officer & Director
Peter Barrett Chairman
Scott Plevy Chief Scientific Officer
Richard Riese Chief Medical Officer
Michael F. Powell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNLOGIC, INC.-69.04%69
CSL LIMITED35.54%77 980
BIOGEN INC.-26.87%40 589
ALEXION PHARMACEUTICALS1.08%22 066
SAMSUNG BIOLOGICS CO LTD--.--%19 301
GRIFOLS19.13%18 295